JUN 29, 2015 2:19 PM PDT

New Way to Combat Cancer

WRITTEN BY: Ilene Schneider
While cancer research often focuses on genetic mutations that cause different cancers, a new study published in the journal Cancer Cell and reported in Medical News Today "targets the pathways that hungry cancer cells use to satisfy their voracious appetite for energy." In an effort to grow fast and divide, cancer cells have preferred methods to obtain energy. The study concentrates on a way to undermine them (http://www.medicalnewstoday.com/articles/296024.php).
A new drug is designed to keep cancer cells from accessing metabolic pathways, thus keeping them from growing.
Researchers at Saint Louis University, in Missouri, focused on two metabolic pathways to which senior author Thomas Burris, professor and chair of pharmacology and physiology, says cancer cells are "addicted." According to Prof. Burris, "They need tools to grow fast, and that means they need to have all of the parts for new cells and they need new energy." Cancer cells use two pathways to make the parts they require -- the Warburg effect, which speeds up the use of glucose, and lipogenesis, which gives the cells a way to make their own fats for rapid growth.

According to the Medical Dictionary (http://medicaldictionary.thefreedictionary.com), the Warburg effect is the observation, first made by Otto Heinrich Warburg, that most malignantcells obtain their energy from anaerobic metabolism, at rates of glycosis of as much as 200 times greater than oxidative metabolism of pyruvate in mitochondria. This effect caused Warburg to conclude that the fundamental change in cancer was metabolic, rather than genetic. According to the same source, lipogenesis is the formation of fatty acids from carbohydrate, mainly in the liver, after which fatty acids can be formed from carbohydrates and then combined with triglycerol to form triglycerides.

The research team explained how a small molecule, called SR9243, that "selectively targets these two pathways stopped cancer cell growth in cultured tumor cells in the lab and in human tumor cells grown in animals without harming healthy tissue or inducing weight loss, inflammation or liver damage." SR9243 started as an anticholesterol drug candidate. It targets fat synthesis in cells to keep them from producing their own fat, suppresses abnormal glucose consumption and cuts off the energy supply of cancer cells. By turning down the genes that drive these processes, the drug stops them. When cancer cells are cut off from their favorite energy sources, they cannot make the parts they need to thrive. Thus, they die. However, "because the Warburg effect is not a feature of normal cells and because most normal cells can get their fat from outside," the drug only kills cancer cells and does not harm healthy cells.

According to Prof. Burris, some cancers are more sensitive to the drug than others. He said that SR9243 "worked very well on lung, prostate and colorectal cancers, and it worked to a lesser degree in ovarian and pancreatic cancers." While it also seems to work on glioblastoma, a type of brain cancer that is very hard to treat, it is not able to cross the blood-brain barrier very effectively. The team is trying to find a way to help it to do that. SR9243 may also increase the effectiveness of existing chemotherapy drugs when used in tandem with them.
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUL 08, 2021
Cancer
Activating p53 May Boost Efficacy of Cancer Immunotherapy
JUL 08, 2021
Activating p53 May Boost Efficacy of Cancer Immunotherapy
Pharmacological activation of the p53 protein in cancer cells leads to an anti-tumor immune response in lab tests. These ...
AUG 13, 2021
Cancer
Ultrasound Triggers Immunotherapy to Destroy Tumors
AUG 13, 2021
Ultrasound Triggers Immunotherapy to Destroy Tumors
An immunotherapy engineered to be triggered by ultrasound beams significantly slows the growth of cancerous tumors in mi ...
SEP 27, 2021
Cancer
Inflammation Promotes Pancreatic Cancer Progression
SEP 27, 2021
Inflammation Promotes Pancreatic Cancer Progression
Inflammation occurs when the immune response, including immune cells and mediators they produce, protect you from danger ...
SEP 23, 2021
Drug Discovery & Development
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
SEP 23, 2021
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
Last week, the United States Food and Drug Administration (FDA) granted approval for the first oral therapy to ...
NOV 04, 2021
Cancer
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
NOV 04, 2021
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
Despite the incremental success immune checkpoint inhibitors (ICI) have attributed to the cancer treatment landscape rec ...
NOV 24, 2021
Cannabis Sciences
Can Cannabis Treat Chemotherapy-induced Peripheral Neuropathy?
NOV 24, 2021
Can Cannabis Treat Chemotherapy-induced Peripheral Neuropathy?
Platinum-based chemotherapies such as oxaliplatin are used to treat gastrointestinal tumors, especially in the advanced ...
Loading Comments...